European move finalised as Liverpool sell to Leverkusen
Liverpool Confirm Quansah Departure
Liverpool have confirmed the departure of Jarell Quansah to Bayer Leverkusen in a permanent transfer that could reach a total of £35 million. The 22-year-old leaves Anfield after making 58 senior appearances, following nearly 17 years at the club.
The initial fee is believed to be £30 million, with a further £5 million in performance-related add-ons. However, reports in Germany suggest the base fee is closer to €30 million (£25.7 million), with the rest accounted for through bonuses.
Strategic Deal Includes Buy-Back Clause
Quansah's move includes a buy-back clause, which will become active from 2027. The clause is reportedly set at €60 million (around £51.4 million), giving Liverpool a potential opportunity to re-sign the player in the future should he continue to develop in the Bundesliga.
Photo: IMAGO
Advertisement
Sources close to the deal view the structure as reflective of Liverpool's desire to retain some level of control over Quansah's future, while allowing the player regular first-team minutes at a high-performing European club.
Exit Follows Breakthrough Season
Quansah played a notable role in Liverpool's 2023/24 campaign, emerging as a reliable option in defence during a season in which the club secured the Premier League title under Arne Slot.
His departure marks the end of a long association with the club he joined as a five-year-old.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 minutes ago
- Yahoo
Skills shortage jeopardising pledge to build 1.5 million homes, report warns
A critical shortage of skilled workers is jeopardising the Government's pledge to build 1.5 million new homes by 2029, according to research. Skills development organisation City & Guilds surveyed employers, training providers and employees, finding 76% of construction firms are struggling to recruit the skilled people they need, with 84% agreeing the industry is suffering from critical skills shortages. The latest outlook from the Construction Industry Training Board suggests the industry needs to recruit 239,300 workers by 2029 to be able to meet the projected demand for the 1.5 million homes target. More than half (54%) of employers do not think the sector has the workforce it needs to meet this target, with the same percentage also putting into doubt the sector's ability to deliver net zero housing goals. Kirstie Donnelly, chief executive of City & Guilds, said: 'We can't build 1.5 million homes without the people to deliver it. We urgently need to reset how we attract, train, and upskill talent across the construction sector, with flexible routes, smarter investment, and collaboration between industry, education and Government. 'With the Government signalling a clear intention to reduce reliance on overseas workers, investing in and nurturing skills isn't optional – it's critical.' Jambu Palaniappan, chief executive at Checkatrade, said: 'The vision of modern, energy-efficient homes that are fit for 21st-century Britain will remain out of reach unless we tackle the critical trade skills gap head-on. 'Government is taking some important steps to address the problem and industry needs to play its part too. Checkatrade is piloting initiatives across the country, from boosting construction apprenticeships through to helping existing trades build new skills as more consumers look to make their homes greener and cheaper to run.'
Yahoo
18 minutes ago
- Yahoo
Medimaps Group Launches In Europe TBS Osteo Next-Generation Software For Advanced Bone Microarchitecture Assessment
New TBS Osteo Advanced next-generation software enhances fracture risk detection beyond standard of care in osteoporosis, a silent disease affecting over 32 million Europeans1 TBS Osteo Advanced next-generation software to be rolled-out across Europe Broad clinical adoption reinforces TBS Osteo leadership in bone microarchitecture evaluation for fracture risk assessment Subscription-based model offers ongoing services and access to future clinical innovations GENEVA, July 03, 2025--(BUSINESS WIRE)--Medimaps Group S.A., a global leader in AI-driven bone microarchitecture imaging solutions, announces the European launch of its MDR-cleared next-generation TBS Osteo Advanced software. Following the product launch in the United States last month, this next milestone reflects the company's commitment to advancing osteoporosis detection and bone health management worldwide. The TBS Osteo Advanced software delivers refined correction for soft tissue thickness anterior to the lumbar spine, ensuring inclusivity of TBS assessment across a wide range of body phenotypes. It also introduces new system management capabilities, allowing hospitals and healthcare networks to centrally manage the TBS software on their DXA systems fleet, and to standardize workflows across multiple locations. These improvements enhance operational efficiency, streamline clinical processes, and ensure consistent patient care. TBS Osteo is available through a convenient subscription model, a flexible option providing customers with eligibility for software updates, new features and support services. This approach ensures healthcare organizations stay up to date with the latest innovations in osteoporosis care. Current TBS Osteo users have the possibility to upgrade to the next generation version and to take advantage of the new capabilities. "The TBS Osteo next-generation software has been developed with busy radiology professionals in mind for a maximum of clinical output with a minimum of logistics. The software is seamlessly integrated into the clinical workflow and performed at time of DXA scan. This approach sets TBS Osteo apart from competition," said Univ. Prof. Dr. Didier Hans, CEO and Co-founder of Medimaps Group. "TBS Osteo delivers within seconds a comprehensive report combining BMD and clinical factors, providing results beyond the standard of care. Adopted by many top hospitals across the world, including in the U.S., DXA and TBS Osteo have become the gold standard to detect and monitor osteoporosis." Since its initial launch in 2012, TBS Osteo has been widely adopted across the world, to support the assessment and management of osteoporosis. The software is backed by over 1,400 peer-reviewed publications and endorsed by more than 30 national and international osteoporosis assessment and management guidelines. In Europe, the software has received clearance from the Medical Device Regulation (MDR) and remains the only approved medical software for bone microarchitecture evaluation in clinical practice. Osteoporosis is a condition that weakens bones and increases the risk of fractures. Fractures due to osteoporosis have a devastating impact on millions of people worldwide and result in enormous socio-economic costs to society and healthcare systems. According to the International Osteoporosis Foundation, approximately 32 million Europeans aged 50 or over have osteoporosis. The annual number of osteoporotic fractures across the European Union, Switzerland, and the United Kingdom is projected to rise from 4.33 million in 2019 to 5.34 million by 2034 - an increase of over 1 million fractures annually¹. Despite the availability of effective treatments to reduce fracture risk, only 1 in 5 patients who experience an osteoporotic fracture are diagnosed or receive appropriate therapy¹. References International Osteoporosis Foundation (IOF), Last accessed: June 24, 2025 About Medimaps Group Founded by medical practitioners and clinical researchers, Medimaps combines Swiss innovation with a global presence to lead in bone health management. We provide healthcare professionals worldwide with advanced AI-driven software that enables comprehensive bone microarchitecture assessment. Our passion for musculoskeletal health is underpinned by scientific knowledge, collaborations with world-class academics, clinicians, industry partners, and direct patient engagement. The science behind our cutting-edge imaging applications and clinical evidence forms the core of our company's DNA. Medimaps Group, headquartered in Geneva, Switzerland, has offices in the United States and France. Its U.S. affiliate, Medimaps Group USA LLC, markets the company products and services. Learn more at View source version on Contacts Saoyuth Nidh Global Corporate Communications ManagerMob: +41 79 969 77 57snidh@
Yahoo
18 minutes ago
- Yahoo
Record date for reverse share split in Fingerprint Cards AB (publ)
At the Annual General Meeting of Fingerprint Cards AB (publ) ('FPC' or the 'Company') held on June 24, 2025, a resolution was passed to carry out a reverse share split, whereby two thousand (2,000) existing shares will be consolidated into one (1) new share (reverse split 1:2,000). The AGM also resolved to authorize the Board of Directors to determine the record date for the reverse split. The Board has decided that the record date for the reverse split will be July 11, 2025. As a result of the reverse split, FPC's B-shares will change its ISIN code. As of July 10, 2025, the B-shares will be traded under the new ISIN code SE0025420235. From this date, the share price will reflect the effect of the reverse split. Following the reverse split, the total number of shares in the Company will decrease from 15,175,375,766 shares (7,875,000 A-shares and 15,167,500,766 B-shares) and 15,246,250,766 votes to 7,587,687 shares (3,937 A-shares and 7,583,750 B-shares) and 7,623,120 votes. Each share will have a quota value of SEK 21.353477 after the reverse split. Shareholders will automatically receive a new, lower number of shares in proportion to their holdings as of the record date on July 11, 2025. Shareholders whose holdings of B-shares on the record date are not evenly divisible by 2,000 will, in accordance with the AGM's resolution, receive additional B-shares free of charge from the Company to ensure their holdings are evenly divisible by 2,000. The provision of these B-shares will be handled by Euroclear Sweden AB, and no further action is required by the shareholders. Timeline for the reverse share split: July 9, 2025 – Last day of trading in Fingerprint's share before the reverse split. July 10, 2025 – First day of trading in Fingerprint's share after the reverse split. This means that the share price from this day onward will reflect the effect of the reverse split. July 11, 2025 – Record date for the reverse split. For further information, please contact: Adam Philpott, CEO Investor Relations: +46(0)10-172 00 10, investrel@ Press: +46(0)10-172 00 20, press@ About FPC Fingerprint Cards AB (FPC) is a global biometrics leader, offering intelligent edge to cloud biometrics. We envision a secure, seamless world where you are the key to everything. Our solutions – trusted by enterprises, fintechs, and OEMs – power hundreds of millions of products, enabling billions of secure, convenient authentications daily across devices, cards, and digital platforms. From consumer electronics to cybersecurity and enterprise, our cloud-based identity management platforms support multiple biometric modalities, including fingerprints, iris, facial, and more. With improved security and user experience, we are driving the world to passwordless. Discover more at our website and follow us on LinkedIn and X for the latest updates. FPC is listed on Nasdaq Stockholm (FING B). Attachment 250703 - Decision record dateError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
